Evolus (EOLS) Competitors $7.19 -0.32 (-4.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.19 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. ADPT, TVTX, IMCR, MESO, SRPT, APGE, VCEL, BHVN, EWTX, and AUPHShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Adaptive Biotechnologies (ADPT), Travere Therapeutics (TVTX), Immunocore (IMCR), Mesoblast (MESO), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Adaptive Biotechnologies Travere Therapeutics Immunocore Mesoblast Sarepta Therapeutics Apogee Therapeutics Vericel Biohaven Edgewise Therapeutics Aurinia Pharmaceuticals Adaptive Biotechnologies (NASDAQ:ADPT) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Which has more volatility and risk, ADPT or EOLS? Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Which has higher earnings & valuation, ADPT or EOLS? Evolus has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$205.22M9.36-$159.49M-$0.82-15.38Evolus$266.27M1.75-$50.42M-$0.98-7.34 Is ADPT or EOLS more profitable? Evolus has a net margin of -22.31% compared to Adaptive Biotechnologies' net margin of -59.07%. Adaptive Biotechnologies' return on equity of -60.93% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Evolus -22.31%-759.04%-24.63% Does the media prefer ADPT or EOLS? In the previous week, Evolus had 5 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 14 mentions for Evolus and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.33 beat Evolus' score of 0.91 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ADPT or EOLS? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 5.9% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer ADPT or EOLS? Adaptive Biotechnologies presently has a consensus target price of $12.38, suggesting a potential downside of 1.86%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 195.55%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryAdaptive Biotechnologies beats Evolus on 10 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$485.79M$10.83B$5.87B$10.14BDividend YieldN/A1.83%5.68%4.59%P/E Ratio-7.3421.1374.5225.93Price / Sales1.7530.79548.33126.97Price / CashN/A24.8137.5660.44Price / Book79.893.5212.166.29Net Income-$50.42M$210.50M$3.28B$270.77M7 Day Performance-6.14%-0.18%0.87%3.88%1 Month Performance10.45%1.09%4.96%4.88%1 Year Performance-58.89%-10.96%60.74%26.01% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.1962 of 5 stars$7.19-4.3%$21.25+195.5%-56.3%$485.79M$266.27M-7.34170Short Interest ↓ADPTAdaptive Biotechnologies3.6655 of 5 stars$12.54-2.4%$12.38-1.3%+193.3%$1.96B$178.96M-15.29790Positive NewsTVTXTravere Therapeutics2.9769 of 5 stars$21.20-2.0%$33.43+57.7%+86.3%$1.93B$233.18M-10.39460News CoveragePositive NewsAnalyst ForecastIMCRImmunocore1.8525 of 5 stars$36.64-1.5%$56.89+55.3%+6.7%$1.87B$310.20M-91.60320MESOMesoblast1.8209 of 5 stars$14.55+1.1%$18.00+23.7%+132.7%$1.84B$17.20M0.0080Gap DownSRPTSarepta Therapeutics4.4363 of 5 stars$17.60-5.9%$43.50+147.2%-86.1%$1.83B$1.90B-20.231,372Trending NewsAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.9008 of 5 stars$38.42+1.5%$97.29+153.2%-25.0%$1.75BN/A-9.3091News CoveragePositive NewsVCELVericel3.2 of 5 stars$33.22-2.4%$60.40+81.8%-27.3%$1.72B$237.22M276.86300Positive NewsBHVNBiohaven3.2663 of 5 stars$14.50-8.7%$55.71+284.4%-61.0%$1.68BN/A-1.89239Trending NewsHigh Trading VolumeEWTXEdgewise Therapeutics2.7858 of 5 stars$14.88-4.4%$40.55+172.5%-19.0%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9484 of 5 stars$12.30-0.8%$12.00-2.4%+93.6%$1.63B$235.13M28.61300News CoveragePositive News Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Travere Therapeutics Competitors Immunocore Competitors Mesoblast Competitors Sarepta Therapeutics Competitors Apogee Therapeutics Competitors Vericel Competitors Biohaven Competitors Edgewise Therapeutics Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts